J&J Wins Second California Talc Bellwether – Split Verdicts Complicate the Path Forward

Johnson & Johnson secured an important victory in California’s talc litigation on June 5, 2026, when a Los Angeles jury returned a defense verdict in the second bellwether trial involving claims that the company’s talc-based products caused ovarian cancer. 

The case was brought by the estates of Mary Owens, Bonnie Tienken, and Geneva Williams. Their families alleged that decades of Johnson’s Baby Powder use led to ovarian cancer and argued that J&J had long concealed the risks associated with its products.

After weeks of testimony and competing expert opinions on both causation and corporate conduct, the jury sided with Johnson & Johnson. Ten of the twelve jurors found in favor of the defense, concluding that the company was not negligent. The result marks J&J’s first bellwether win in California’s coordinated ovarian-cancer talc proceedings. It also arrives at a critical stage in one of the largest and most closely watched mass-tort litigations in the country.

A Tale of Two Verdicts

The significance of the June verdict becomes clearer when viewed alongside the outcome of the first California bellwether trial.

Just six months earlier, in December 2025, a different Los Angeles jury delivered a major victory for plaintiffs. That jury awarded approximately $40 million to Monica Kent and Deborah Schultz, both of whom alleged that long-term use of Johnson’s Baby Powder caused their ovarian cancer. The December jury found Johnson & Johnson liable on negligence, failure-to-warn, and false-representation claims. Plaintiffs successfully relied on internal corporate documents dating back to the 1960s and 1970s, arguing that the company knew its talc products could be contaminated with asbestos and failed to adequately warn consumers.

That verdict was widely viewed as a turning point. It represented the first plaintiff victory in California’s coordinated ovarian cancer bellwether program and gave momentum to arguments centered on corporate knowledge and concealment.

Now, six months later, a jury in the same courthouse has reached the opposite conclusion. The contrast could hardly be sharper.

What the Split Means

For PI attorneys tracking this litigation, back-to-back contradictory verdicts are the headline. Bellwether trials are not binding on other plaintiffs, but they do critical work in mass torts. They test evidence, shape expert strategy, and calibrate settlement talks. A sweep in either direction would have sent a clear signal. A one-one split does the opposite; it introduces uncertainty that cuts both ways.

Plaintiff firms can still point to the $40 million December verdict as proof that juries can be persuaded by the science and the corporate-concealment story. J&J gains meaningful leverage from this win, as the same arguments, presented to a comparable jury pool, do not always land. The company has consistently maintained that its talc products are safe, contain no asbestos, and do not cause cancer, a position it reiterated after the June verdict.

From a settlement standpoint, the mixed record reduces the predictive value of either result. A string of plaintiff wins would have pushed J&J harder toward a comprehensive resolution. This pressure is now less acute. For the defense, this verdict gives a credible counter-narrative heading into future trials and mediations.

Looking Ahead

The deeper question is what drove the divergence between these two verdicts. Differences in plaintiff profiles, expert presentation, jury selection, and trial strategy all likely mattered; understanding those variables will be essential for plaintiff counsel preparing the next wave of cases.

With tens of thousands of talc-related claims still pending nationwide, including a growing federal MDL docket in New Jersey, California’s bellwether program is doing exactly what it was designed to do, which is exposing the fault lines before the stakes get even higher. Neither side has established a decisive advantage. The next California bellwether will be watched closely by both plaintiff firms and corporate defendants, and its outcome may shape the broader resolution more than either of the first two trials.

California Talc Litigation – Key Facts at a Glance

The core plaintiff argument: J&J knew as far back as the 1960s that its talc products could be contaminated with asbestos and failed to warn consumers, causing ovarian cancer in long-term users.

The core defense argument: The science does not establish a causal link between talc use and ovarian cancer, and no major U.S. health organization has documented a clear connection.

How many cases are pending? 60000+ talc-related claims remain active nationwide, with a significant federal MDL consolidated in New Jersey running parallel to the California state court proceedings.